GlassScriptPhysician profile
Thomas Arthur Moore
NPI 1699734418
$890.51
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $184 · 2021: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $116.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.05 | 2019-2020 | |
| Pfizer INC. | $101.80 | 2019-2020 | |
| Medtronic, INC. | $84.59 | 2021 | |
| Allergan, INC. | $59.15 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.63 | 2019 | |
| Novo Nordisk INC | $46.62 | 2019-2020 | |
| Abbvie INC. | $39.53 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $33.49 | 2019 | |
| Merck Sharp & Dohme LLC | $26.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.87 | 2019-2020 | |
| Amgen INC. | $13.52 | 2019 | |
| Lilly USA, LLC | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.